CASI Pharmaceuticals, Inc. (CASI) Is At $3.56 Formed Wedge; 4 Analysts Covering Aimmune Therapeutics, Inc. (AIMT)

Among 4 analysts covering Aimmune Therapeutics (NASDAQ:AIMT), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aimmune Therapeutics had 5 analyst reports since August 31, 2015 according to SRatingsIntel. Piper Jaffray maintained Aimmune Therapeutics, Inc. (NASDAQ:AIMT) rating on Tuesday, November 17. Piper Jaffray has “Overweight” rating and $38.0 target. Credit Suisse initiated Aimmune Therapeutics, Inc. (NASDAQ:AIMT) on Monday, August 31 with “Outperform” rating. Bank of America initiated the shares of AIMT in report on Monday, August 31 with “Buy” rating. The rating was initiated by JMP Securities on Monday, September 26 with “Mkt Outperform”. The stock has “Overweight” rating by Piper Jaffray on Monday, August 31. See Aimmune Therapeutics, Inc. (NASDAQ:AIMT) latest ratings:

CASI Pharmaceuticals, Inc. (CASI) formed wedge up with $3.81 target or 7.00% above today’s $3.56 share price. CASI Pharmaceuticals, Inc. (CASI) has $248.86M valuation. The stock decreased 4.56% or $0.17 during the last trading session, reaching $3.56. About 171,321 shares traded. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has declined 17.65% since February 28, 2017 and is downtrending. It has underperformed by 34.35% the S&P500.

Investors sentiment decreased to 1.14 in Q3 2017. Its down 0.53, from 1.67 in 2017Q2. It dived, as 3 investors sold CASI Pharmaceuticals, Inc. shares while 4 reduced holdings. 4 funds opened positions while 4 raised stakes. 2.39 million shares or 4.17% more from 2.29 million shares in 2017Q2 were reported. Howland Mgmt Llc invested 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Wells Fargo Com Mn owns 68 shares or 0% of their US portfolio. Guggenheim Cap Lc owns 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 12,242 shares. Manatuck Hill Prns Lc reported 15,090 shares stake. Moreover, Wellington Shields Ltd Liability Com has 0.29% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 489,984 shares. Vanguard Grp reported 358,972 shares. Wellington Shields Cap Management Ltd Liability Corp stated it has 0.17% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Raymond James Svcs Advisors Inc has invested 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Jpmorgan Chase & holds 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 9 shares. Royal Fincl Bank Of Canada owns 17,572 shares. Bankshares Of America De reported 0% stake. Next Fincl Gru Incorporated invested 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Moreover, Moors & Cabot has 0.01% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Everett Harris Ca holds 0% or 10,002 shares. Focused Wealth Management Incorporated holds 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 45 shares.

Among 2 analysts covering CASI Pharmaceuticals Inc (NASDAQ:CASI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CASI Pharmaceuticals Inc has $4.5 highest and $2.0 lowest target. $4.25’s average target is 19.38% above currents $3.56 stock price. CASI Pharmaceuticals Inc had 5 analyst reports since October 29, 2015 according to SRatingsIntel. The rating was initiated by H.C. Wainwright on Thursday, October 29 with “Buy”. The firm has “Buy” rating by Maxim Group given on Thursday, September 22. The stock of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) earned “Buy” rating by H.C. Wainwright on Tuesday, January 16. Maxim Group maintained CASI Pharmaceuticals, Inc. (NASDAQ:CASI) on Monday, August 14 with “Buy” rating.

Analysts await CASI Pharmaceuticals, Inc. (NASDAQ:CASI) to report earnings on March, 30. They expect $-0.03 earnings per share, up 40.00% or $0.02 from last year’s $-0.05 per share. After $-0.03 actual earnings per share reported by CASI Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. The company has market cap of $1.81 billion. The Company’s lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. It currently has negative earnings. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics.

The stock increased 5.18% or $1.56 during the last trading session, reaching $31.67. About 2.14 million shares traded or 188.77% up from the average. Aimmune Therapeutics, Inc. (NASDAQ:AIMT) has risen 32.49% since February 28, 2017 and is uptrending. It has outperformed by 15.79% the S&P500.